ADAM17 and Miyoshi myopathy: Future systemic biology analyses would shed more light on the underlying interactions of SPAG5 and FOXM1/ADAM17/NOTCH1 signaling, and could help in developing novel diagnostic and therapeutic strategies for MM management.